Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway altered DIPG/DMG.

Neuro-oncology - 1 Jan 2026

Jiang Zhuang, Xie Luyang, Zhou Hang, Geng Yibo, Xiao Xiong, Li Tian, Deng Yuxuan, Zhang Mingxin, Shan Shaobo, Xu Cheng, Zhang Liwei

Abstract excerpt

BACKGROUND: Diffuse midline gliomas (DMGs), particularly diffuse intrinsic pontine gliomas (DIPGs), are aggressive pediatric brain tumors with a median survival of less than 12 months. Notably, approximately 70% of these tumors harbor P53 pathway alterations, including TP53 or PPM1D mutations. Identifying precision therapies for this subset is crucial. This study aims to employ transcriptomics-guided...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Stem Neoplasms
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Screening Assays

Share to Irinotecan

Share to Transcriptome

Share to Tumor Cells, Cultured

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40973093
DOI: 10.1093/neuonc/noaf216
PMCID: PMC12962651

Genes

TP53
ATR
PPM1D

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway altered DIPG/DMG.PMID 40973093Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic AgentSemantic proximity Read ↗

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.Semantic proximity Read ↗

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity Read ↗

Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma SubpopulationsSemantic proximity Read ↗

Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood EpendymomaSemantic proximity Read ↗

A disease model for Diffuse Intrinsic Pontine Glioma (DIPG) with mutations in TP53 and its application for drug repurposingSemantic proximity Read ↗

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201Semantic proximity Read ↗

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical PerspectiveSemantic proximity Read ↗

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.